Gilles Gallant

Chief Development Officer Mythic Therapeutics

Seminars

Wednesday 5th November 2025
Chair:

Download the Full Event Guide for full details

Tuesday 4th November 2025
Assessing Safety & Efficacy in the Dose Escalation of MYTX-011 Phase 1 KisMET-01 Study
11:00 am
  • Unveiling efficacy data of MYTX-011 from Phase 1 KisMET-01 study
  • Detailing safety and tolerability profile data from expanded patient cohorts
  • Reflecting on the reasoning and rationale for MYTX-011 dose escalation
Gilles Gallant - 16th World ADC San Diego